Gemphire Therapeutics Inc (NASDAQ:GEMP)’s stock price traded up 8.6% during trading on Friday . The stock traded as high as $0.38 and last traded at $0.38, 324,200 shares changed hands during mid-day trading. An increase of 162% from the average session volume of 123,752 shares. The stock had previously closed at $0.35.
Separately, ValuEngine upgraded shares of Gemphire Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
The company’s fifty day simple moving average is $0.36 and its 200 day simple moving average is $0.65.
Gemphire Therapeutics Company Profile (NASDAQ:GEMP)
Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy.
Featured Article: How Buying a Call Option Works
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.